The content velocity trap: Why producing more is making your HCP engagement worse
Only one-third of HCPs say customer-facing content meets their needs, while most pharma executives believe their engagement strategies work. The old formula of “more content = more engagement” is not working, but many companies are still ignoring this fact.
In this article, we address how to fix this broken upstream process without losing even more time, resources, and effort in the process.
Where content gets lost: Three gaps
Content velocity breaks at three predictable failure points. As explored in a recent conversation between Nataliya Andreychuk, CEO of Viseven and the host of Pharma Talks, and Mark Watson, the co-founder of Fractal Force, most companies have fallen into at least one of these three gaps, with many dealing with all three at the same time:
Gap one: Between production and MLR
When the time comes for review, MLR teams often receive the content that’s not prepared for the next stage of review. Instead of checking for compliance issues, MLR experts end up dealing with even more problems, such as unstructured content, lack of proper references, grammatical and stylistic errors, etc. As a result, reviews take weeks, which is often not the MLR team’s fault.
Gap two: Between functions
Marketing runs a campaign, Medical Affairs prepares an evidence update, and Commercial conducts a rep visit. All of these are important actions, but often only the members of the team working on those projects know about them. As a result, HCPs receive three uncoordinated messages from the same company in the same week.
Gap three: Between global and local
It is a normal practice for many companies in pharma to create content centrally. What happens after, though, is not always efficient, because in many companies, localisation is often treated as an afterthought, sometimes even becoming a separate project with no structural connection to the original piece.
Why AI does not close these gaps and can widen them
AI can’t produce a high-quality piece of content if it feeds on low-quality data. If your knowledge base is a collection of unstructured PDFs, inconsistently tagged assets, and brand guidelines living in three different systems, AI will only scale up the chaos.
As Prasant Vijaykumar, chief strategy officer of Viseven, noted in one Pharma Talks episode, “the MLR issue is not solved by faster generation — it is solved by changing what goes in at the start”. Modular content is not simply an operational preference. It is the structured data layer that makes AI-powered content development reliable, traceable, and compliant.
What is content velocity and how to measure it
Content velocity has been an obsession for many pharma teams for years. However, it is a lot more than just a number that represents the number of assets produced every month. When teams go beyond that, they can measure content velocity to know how quickly the right content reaches the right HCP at the right moment.
When content velocity is looked at from this angle, localisation is not seen as a downstream task anymore, but as a core velocity metric instead. As Vijaykumar said in the podcast, “How fast can I localise?” is a question that is rarely included in content KPIs when it most certainly should be. The speed of localisation is one of the clearest indicators of whether a supply chain is genuinely connected — or just seems connected on paper.
What connected content operations look like in practice
In pharma, many content operations don’t fail at the execution stage. The vision exists, ambition is there, but something is missing. Companies that solve this problem typically do so by building content operations in three layers. Let’s go through each one.
Layer 1: Structured knowledge base
First, a foundation needs to be lain: content that can be trusted, reused, and traced. When a claim can be reused without going back through it every time, one of the most expensive inefficiencies in the entire lifecycle has been eliminated. Every piece of content buried in a folder somewhere adds to expenses.
Layer 2: Shared intelligence layer across functions
Marketing, Medical Affairs, and Commercial each hold a piece of the puzzle when it comes to understanding healthcare professionals. When those teams operate in silos, each lacks information about HCP interactions and ends up starting from zero. On the contrary, when every function is informed about the next touchpoint and interaction, the experience provided becomes coherent and genuine.
Layer 3: Localisation built into the supply chain
Neglecting localisation till the very end erases all of the effort that was put into the content prior. Adapting content should not be a separate process, even if a completely different team is working on it. Localisation infrastructure must be embedded from the beginning, in the taxonomy, in modular content, and in the workflow design.
A practical self-assessment for pharma teams
Before planning the next cycle or content sprint, do this one thing: find the place in the content supply chain where content waits longest, where it arrives incomplete, and takes double the time needed to pass reviews. Don’t think of this waiting as a tech problem. It’s just a point where structure ends, and chaos begins. It is where:
- Highly skilled reviewers are spending more time on incomplete submissions instead of reviews;
- Localisation teams are rebuilding instead of adapting;
- Content experts are starting from a blank page because there is no access to approved versions.
Fixing that one single bottleneck before moving on to investing in the next AI tool or adding another hyped-up channel to the roster will do a lot more for HCP engagement than just another sprint. As Vijaykumar observed, removing just the right blocker can accelerate the entire workflow by 50%, and this is just an estimate: most teams can do even better.
Closing thoughts
The organisations that win the content race are not the ones that produce the most. They are the ones that built a system where content moves without friction — from idea through approval to HCP experience and back as insights. For teams rethinking how content moves from strategy to engagement, the next step is not simply producing more. It is to identify where the supply chain breaks.
To learn more about AI-native content supply chain transformation and how to adopt a holistic approach to content strategy, contact our team for a detailed consultation.
About Viseven
Viseven is a global MarTech company specializing in digital content solutions for the Life Sciences and Pharma industries. With over 15 years of expertise, Viseven empowers pharmaceutical companies and their production agencies with AI-driven content management and automation solutions.
Our flagship eWizard Platform streamlines content planning, creation, distribution, and management—enhancing efficiency, reducing operational costs, and accelerating brand time-to-market. Designed for omnichannel and multichannel engagement, eWizard optimizes campaign management, data collection, and performance analysis, ensuring continuous message improvement for Brand Managers and Content Operations teams.
Visit us at viseven.com or follow us on social media: LinkedIn
